Adenovirus-Mediated Expression of Secretable Glucose-Regulated Protein 94 Enhances Cancer Radiation Therapy

Recent research from the United States has shown great promise in using tumor-derived glucose-regulated protein 94 (GRP94/gp96) as a tumor vaccine. However, current protein-based approaches often require large quantities of tumor tissue, which may not be feasible. To address this challenge, scientists at Duke University explored the therapeutic efficacy of a combined GRP94/gp96-based genetic immunotherapy and radiation therapy strategy in a highly metastatic 4T1 murine mammary cancer model. They constructed an adenovirus encoding a modified, secretable form of GRP94 and evaluated its effects in various antitumor experiments.

Key Takeaways:

• The therapeutic efficacy of a combined GRP94/gp96-based genetic immunotherapy and radiation therapy strategy was explored in a highly metastatic 4T1 murine mammary cancer model.
• An adenovirus encoding a modified, secretable form of GRP94 (AdsGRP94) was constructed and used as a vaccine to prevent tumor growth.
• Vaccination with lethally irradiated, AdsGRP94-infected 4T1 cells completely prevented subsequent tumor growth from challenge inoculations of as many as 10^7 cells per mouse.
• The combination of vaccination with radiation therapy and intratumoral (i.t.) AdsGRP94 injections markedly inhibited local tumor growth and pulmonary metastasis.
• Complete tumor regression was observed in some cases, and the mice remained tumor-free up to 10 months after initial therapy.
• The study found that the AdsGRP94-based immunotherapy and radiation therapy may be a potentially effective strategy for cancer treatment.
• Shanling Liu and colleagues at Duke University conducted the study, which was published in Cancer Research (Enhancement of cancer radiation therapy by use of adenovirus-mediated secretable glucose-regulated protein 94/gp96 expression, Cancer Res, 2005;65(20):9126-9131).

Statistics:

• The vaccination with lethally irradiated, AdsGRP94-infected 4T1 cells completely prevented subsequent tumor growth from challenge inoculations of as many as 10^7 cells per mouse.
• The combination of vaccination with radiation therapy and i.t. AdsGRP94 injections resulted in a 100% complete tumor regression in some cases.
• The mice remained tumor-free up to 10 months after initial therapy.
• 4T1 murine mammary cancer model was used in the study.

Sources:

• Liu, S., et al. (2005). Enhancement of cancer radiation therapy by use of adenovirus-mediated secretable glucose-regulated protein 94/gp96 expression. Cancer Research, 65(20), 9126-9131.
• American Association for Cancer Research. (2005). Publisher contact information for the journal Cancer Research.